MYALEPTA® (metreleptin) receives marketing approval by EU for leptin deficiency in lipodystrophy (LD) Patients

 MYALEPTA® (metreleptin) receives marketing approval by EU for leptin deficiency in lipodystrophy (LD) Patients

MYALEPTA® (metreleptin) receives marketing approval by EU for leptin deficiency in lipodystrophy (LD) Patients

Shots:

  • First and only therapy approved for LD patients with confirmed or acquired in adults and children ≥2yrs; partial or acquired LD in adults or children ≥12yrs in Europe after being approved by US FDA in 2014
  • The approval will prove to be a significant advancement for patients in Europe
  • Authorization was on results shown from open –label, single arm study in 48 patients

Click here to read full press release/ article | Ref:  Novelion  | Image: Business Wire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post